• Something wrong with this record ?

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

A. Novakova-Jiresova, K. Kopeckova, L. Boublikova, R. Chloupkova, B. Melichar, L. Petruzelka, J. Finek, O. Fiala, P. Grell, S. Batko, Z. Linke, I. Kiss, J. Prausova, T. Buchler,

. 2020 ; 12 (-) : 5365-5372. [pub] 20200703

Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20022022

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.0-23.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, M0 stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022022
003      
CZ-PrNML
005      
20201204093616.0
007      
ta
008      
201125s2020 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/CMAR.S255332 $2 doi
035    __
$a (PubMed)32753954
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Novakova-Jiresova, Alena $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic.
245    10
$a Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients / $c A. Novakova-Jiresova, K. Kopeckova, L. Boublikova, R. Chloupkova, B. Melichar, L. Petruzelka, J. Finek, O. Fiala, P. Grell, S. Batko, Z. Linke, I. Kiss, J. Prausova, T. Buchler,
520    9_
$a Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.0-23.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, M0 stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kopeckova, Katerina $u Department of Oncology, University Hospital in Motol, Charles University, Prague, Czech Republic.
700    1_
$a Boublikova, Ludmila $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Chloupkova, Renata $u Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Petruzelka, Lubos $u Department of Oncology, General Faculty Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Grell, Peter $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Batko, Stanislav $u Department of Oncology, University Hospital in Motol, Charles University, Prague, Czech Republic.
700    1_
$a Linke, Zdenek $u Department of Oncology, University Hospital in Motol, Charles University, Prague, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Prausova, Jana $u Department of Oncology, University Hospital in Motol, Charles University, Prague, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic.
773    0_
$w MED00165412 $t Cancer management and research $x 1179-1322 $g Roč. 12, č. - (2020), s. 5365-5372
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32753954 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201204093613 $b ABA008
999    __
$a ind $b bmc $g 1591730 $s 1112694
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c - $d 5365-5372 $e 20200703 $i 1179-1322 $m Cancer management and research $n Cancer manag. res. $x MED00165412
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options